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PodocyteNumerous studies have shown that the NALP3 inﬂammasome plays an important role in various immune and
inﬂammatory diseases. However, whether the NALP3 inﬂammasome is involved in the pathogenesis of diabetic
nephropathy (DN) is unclear. In our study, we conﬁrmed that high glucose (HG) concentrations induced NALP3
inﬂammasome activation both in vivo and in vitro. Blocking NALP3 inﬂammasome activation by NALP3/ASC
shRNA and caspase-1 inhibition prevented IL-1β production and eventually attenuated podocyte and glomerular
injury under HG conditions. We also found that thioredoxin (TRX)-interacting protein (TXNIP), which is a pro-
oxidative stress and pro-inﬂammatory factor, activated NALP3 inﬂammasome by interacting with NALP3 in
HG-exposed podocytes. Knocking down TXNIP impeded NALP3 inﬂammasome activation and alleviated
podocyte injury caused by HG. In summary, the NALP3 inﬂammasomemediates podocyte and glomerular injury
in DN, moreover, TXNIP participates in the formation and activation of the NALP3 inﬂammasome in podocytes
during DN, which represents a novel mechanism of podocyte and glomerular injury under diabetic conditions..© 2014 Elsevier B.V. All rights reserved.1. Introduction
Diabetic nephropathy (DN) is the most common chronic microvas-
cular complication of diabetes. Due to its high morbidity and mortality
[1], it has become a primary reason for end stage renal disease (ESRD)
in patients and a major global public health problem [2–4]. Therefore,
understanding the pathogenesis is critical for its prevention and treat-
ment. Podocytes are considered to be the primary cause of the onset
and progression of DN [5–8]. For example, the loss of podocytes was
observed in patients with early and late DN [9,10]. However, the early
pathogenic mechanisms of DN are not fully understood yet.
Immunity and inﬂammation are responsible for the occurrence
and progression of glomerular diseases, particularly podocyte injury
and glomerulosclerosis. The inﬂammasome is deﬁned as an intracel-
lular organelle governing immune and inﬂammatory processes
[11]. Inﬂammasomes are a large family, among which the NALP3
inﬂammasome is a typical member in mammalian cells. The
NALP3 inﬂammasome is composed of NALP3 (NACHT, LRR and PYD
domains-containing protein 3), ASC (apoptosis-associated speck like
protein) and caspase-1. NALP3 can recruit caspase-1 via adapter molec-
ular ASC to form a proteolytic complex “NALP3 inﬂammasome” [12,13]
and each component is essential to inﬂammasome activation [14].ASC is necessary for caspase-1 activation and subsequent mature
interleukin-1β (IL-1β) secretion when responding to various danger-
associated molecular patterns (DAMPs) or pathogen-associated molec-
ular patterns (PAMPs) [11,13,15,16]. IL-1β is primarily produced by
podocytes in the glomeruli [17], and importantly participates in kidney
injury and repair [18]. In podocytes, active caspase-1 is indispensable
for cleaving the inactive pro-IL-1β into its active form [19]. Recently,
the NALP3 inﬂammasome was identiﬁed as a possible therapeutic tar-
get in patients with progressive CKD [20]. Additionally, the NALP3 ago-
nist biglycan, the IL-1 receptor, and cytokines such as IL-1β can all
accelerate renal inﬂammation and ﬁbrosis [21,22]. Yet, it remains to
be explored whether the NALP3 inﬂammasome is involved in podocyte
injury of DN. It is also necessary to determine the early regulatory
mechanisms of the NALP3 inﬂammasome activation and subsequent
podocyte damage.
Recently, it has been shown that NALP3 can interact with thioredoxin
(TRX)-interacting protein (TXNIP), which is related to insulin resistance,
and that TXNIP deletion impedes NALP3 inﬂammasome activation and
subsequent IL-1β production in immune cells [23,24]. The expression of
TXNIP mRNA and protein is highest in the glomeruli and distal nephron
of normal human and rat kidney, and knockdown of TXNIP decreases
oxidative stress [25]. There is a wealth of evidence indicating that TXNIP
is associatedwith glucosemetabolism and diabetes [23,26–28]. However,
it is still unknown that, whether TXNIP can mediate the activation of
NALP3 inﬂammasome and ultimately cause podocyte injury in DN.
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inﬂammasome activation, which plays a vital role in podocyte and
glomerular inﬂammatory damage during DN.
2. Materials and methods
2.1. Animals
All experiments were performed according to the guidelines for use
and care of laboratory animals of National Institutes of Health (NIH),
and approved by the Animal Care and Use Committee (ACUC) of Tongji
Medical College. Caspase-1 knockout (KO) mice were obtained from
Jackson Laboratories (Bar Harbor, Maine, USA). Wide type (WT) mice
and caspase-1 KOmice of eight-week-old, received a single intraperito-
neal injection of streptozotocin (STZ, 150 mg/kg; Enzo Life Sciences,
Ann Arbor, MI, USA). Eight-week-old control mice received only an
injection of citrate buffer. Blood glucose levels were monitored weekly
by glucometer readings. Only mice with stable glucose levels more
than 16.7 mmol/l (95%) were included in the study. After 8 weeks of
experimental diabetes, we placed all mice into metabolic cages and
then collected urine samples after 24 h, before collecting blood samples
and kidney tissues. Urinary albumin and creatininemeasurementswere
performed by Auto-Chemistry Analyzer of DIRUI CS-400B (Changchun,
Jilin, China).
2.2. Cell culture
An immortalized human podocyte cell line was cultured and main-
tained as described previously [29]. Brieﬂy, cells were cultured in RPMI-
1640 medium supplemented with both 10% fetal bovine serum (FBS)
and 100 U/ml penicillin-streptomycin in humidiﬁed 5% CO2 incubator
and ﬁrstly incubated at 33 °C. After the cells reached at 70% conﬂuence,
they were incubated at 37 °C for 2 weeks to allow differentiation before
any experimental manipulations. When differentiated cells had grown
up to 75% conﬂuence, they were transferred to 2% FBS media for 12 h.
These cells were exposed to media containing either normal glucose
(as a control,5.6 mmol/l D-glucose) or high glucose (HG, 30 mmol/l D-
glucose) for 12, 24 and 48 h. Moreover, osmotic pressure control was
used by 24.4 mmol/l mannitol plus 5.6 mmol/l D-glucose.
2.3. NALP3 shRNA, ASC shRNA, and TXNIP siRNA
NALP3 shRNA and ASC shRNA were obtained from Genechem
(Shanghai, China), and they were useful in silencing NALP3/ASC gene
in podocytes. The scrambled shRNA (Genechem, Shanghai, China) was
used as a control. Podocytes were synchronized for 12 h and then tran-
siently transfected with NALP3/ASC shRNA or scrambled shRNA. To
knock down TXNIP, we treated human podocytes with siRNA against
human TXNIP coding region. The target sequences were 5′-AAGCCGTT
AGGATCCTGGCTT-3′ for human siTXNIP and 5′-AATTCTCCGAACGTGT
CACGT-3′ for scrambled siRNA (QIAGEN, Germantown, MD, USA). The
transfection protocolwas done by using lipofectamine 2000 (Invitrogen
Corp., Carlsbad, CA, USA) according to the manufacturer's instruction.
After 24 h, HG (30 mmol/l) was mixed into the medium for the corre-
sponding time to conduct the following experiments.
2.4. Indirect immunoﬂuorescent staining and confocal microscopy
To localize inﬂammasome components with podocyte in the
mouse kidney, frozen tissue slides were used to perform double-
immunoﬂuorescent staining. After ﬁxation for 15 min, the slides
were permeabilized with 0.3% Triton X-100 in PBS for 5 min, blocked
with 5% donkey serum for 30 min, and then incubated overnight at 4 °C
with goat anti-synaptopodin antibody (1:40; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and rabbit anti-NALP3 (1:100; Protein Tech
Group, Chicago, IL), goat anti-synaptopodin antibody (1:40; Santa CruzBiotechnology, Santa Cruz, CA, USA) and rabbit anti-ASC antibody
(1:50; Enzo, Plymouth Meeting, PA, USA), or goat anti-synaptopodin
antibody (1:40; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
mouse anti-caspase-1 antibody (1:50; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Synaptopodinwas used as themarker of podocyte. In ad-
ditional experiments, tissue slides were probed with mouse anti-TXNIP
antibody (1:100; MBL International Co, Woburn, MA, USA) together
with goat anti-synaptopodin antibody (1:40; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) to show the localization of TXNIP and podocytes.
After washing, these slides were incubated with Alexa-488-labeled or
Alexa-647-labeled secondary antibodies for 1 h at room temperature.
After being stained with DAPI, the slides were examined by confocal
laser scanning microscopy (Fluoview FV1000, Olympus, Japan). Separate
staining of Alexa-488-labeled or Alexa-647-labeled secondary antibody
alone was used as negative control. No visible ﬂuorescence was detected
under these conditions, which indicates the speciﬁc staining of above
antibodies. The colocalization was analyzed by the Image Pro Plus 6.0
software (Media Cybernetics, Bethesda, MD, USA).
2.5. Human renal biopsy samples and immunohistochemical studies
Renal biopsy was performed routinely. The patient samples were
obtained from the Department of Nephrology of Union Hospital, Tongji
Medical College, Huazhong University of Science and Technology. Con-
trol sampleswere obtained from the healthy kidney poles of individuals
who underwent nephrectomy due to tumor, without diabetes or any
other renal diseases. All the procedures were approved by the Ethics
Committee of Tongji Medical College, Huazhong University of Science
and Technology.
Parafﬁn-embedded kidney tissue sections were prepared at 4 μm
thicknesses, and stained with antibodies to NALP3, ASC, or caspase-1
according to immunohistochemistry procedure. After staining, random-
ly choosing glomerular cross sections to calculate positively stained area
using Image Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD,
USA). The data were exhibited as integrated optical density (IOD).
2.6. Western blot analysis
Western blot analyses were performed as we described previously
[19]. In brief, proteins from mouse glomeruli or cultured human
podocytes were extracted with RIPA Lysis Buffer (Beyotime, Jiangsu,
China). After boiling for 5 min at 95 °C in 5× loading buffer, 30 μg of
mouse glomeruli protein or 80 μg of cultured human podocyte proteins
were subjected to SDS-PAGE, transferred to PVDF membrane and
blocked for 1 h. The membranes were incubated overnight at 4 °C with
the following primary antibodies of rabbit anti-NALP3 antibody
(1:1000; Protein Tech Group, Chicago, IL), rabbit anti-ASC antibody
(1:50; Enzo, PlymouthMeeting, PA, USA), rabbit anti-caspase-1 antibody
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-
desmin antibody (1:1000; Protein Tech Group, Chicago, IL), rabbit anti-
synaptopodin antibody (1:1000; Protein Tech Group, Chicago, IL),
mouse anti-TXNIP antibody (1:1000; MBL, International Co, Woburn,
MA, USA) or mouse anti-β-actin antibody (1:10000; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). After washing, the membranes were incu-
batedwith horseradish peroxidase-labeled IgG (1:10000) for 1 h at room
temperature. The immunoreactive bands were detected by chemilumi-
nescence methods and visualized on Kodak Omat X-ray ﬁlms.
Densitometric analysis of the images obtained from X-ray ﬁlms was
performed using the Image J software (NIH, Bethesda, MD, USA).
2.7. Caspase-1 activation detection
Caspase-1 activity was detected by a commercial kit (Biovision,
Mountain View, CA, USA), which was used to represent the activation
of NALP3 inﬂammasome. The data were calculated as the fold changes
compared to control cells.
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This detection kit was obtained from Immunochemistry Technol-
ogies (Bloomington, MN, USA). After sample preparation, staining
procedure was conducted according to the instruction described by
the manufacturer.2.9. Direct immunoﬂuorescent staining of F-actin
Todeterminewhether HG-inducedNALP3 inﬂammasome activation
could result in cytoskeleton changes of podocytes, podocytes were
pretreated with caspase-1 inhibitor Z-YVAD-FMK (Z-YVAD; 10 μmol/l;
Biovision, Mountain View, CA, USA) or transfected with NALP3/ASC
shRNA or scrambled shRNA, TXNIP siRNA or scrambled siRNA, and
then exposed to HG (30 mmol/l) for 48 h. The cells were ﬁxed in 4%
paraformaldehyde for 15 min at room temperature after washing,
permeabilized for 5 min with 0.1% Triton X-100 in PBS, and blocked
for 30 min with 5% BSA. F-actin was incubated with rhodamine–
phalloidin (Invitrogen Corp., Carlsbad, CA, USA) for 15 min at room
temperature. The slides were examined by confocal laser scanning
microscopy. The cells with distinct F-actin ﬁbers were counted as we
described previously [30]. Scoring was obtained from 100 podocytes
on each slide in different groups.2.10. Transmission electron microscopy (TEM)
For detection of ultrastructural changes of podocytes, tissue samples
were ﬁxed with 3% glutaraldehyde in 0.1 mol/l phosphate buffer
overnight. All samples were sent to Ultrastructural Pathology Center
of Tongji Medical College for TEM examination.2.11. Light microscopy
To observe renal morphology by light microscopy, the experimental
procedures and speciﬁc scoringmethodwere performed aswedescribed
previously [31].2.12. ELISA for IL-1β in podocytes
After being transfected with ASC/NALP3 shRNA/scrambled shRNA;
TXNIP siRNA/scrambled siRNA, or pretreated with caspase-1 inhibitor
(Z-YVAD), podocytes were incubated with HG (30 mmol/l) for 48 h.
The IL-1β production in supernatant was measured by ELISA assay
according to the protocol described by themanufacturer (R&D Systems,
Minneapolis, MN, USA).2.13. TRX activity
Thioredoxin Reductase Colorimetric Assay Kit was obtained from
Cayman Chemical Company. TRX activity was measured by the insulin
disulﬁde reduction assay as described by the manufacturer.2.14. Statistical analysis
All of the values are expressed as mean ± SEM. Signiﬁcant differ-
ences among multiple groups were examined using ANOVA followed
by a Student–Newman–Keuls post hoc test.χ2 test was used for testing
the signiﬁcance of ratio and percentage data. P b 0.05 was considered
statistically signiﬁcant.3. Results
3.1. The NALP3 inﬂammasome is activated in podocytes of the glomeruli of
both human DN specimens and DN mice
To determine whether NALP3 inﬂammasome is activated in
podocytes of the glomeruli of DN, we ﬁrst analyzed the expression
of NALP3, ASC and caspase-1 in podocytes of the glomeruli of both
human DN specimens and DN mice. By confocal microscopy we
observed that the colocalization of NALP3 inﬂammasome components
with synaptopodin increased in the glomeruli of both human DN spec-
imens and DN mice comparing to their separate controls, even though
the intensity of synaptopodin staining (podocyte marker) decreased
in the glomeruli of DN mice (Fig. 1A–D). The enhanced expression of
NALP3 inﬂammasome components in the glomeruli of DN mice was
conﬁrmed by immunohistochemistry (Fig. 1E, F).
3.2. HG induces NALP3 inﬂammasome activation in cultured human
podocytes
Next, we evaluated whether HG directly activated NALP3
inﬂammasome in cultured human podocytes. It was found that HG
increased NALP3, ASC, active caspase-1 and active IL-1β expression in
a time-dependent manner by Western blot analyses in HG-treated
podocytes (Fig. 2A, B). Mannitol was used to rule out the inﬂuence
of osmotic pressure on NALP3 inﬂammasome (Data not presented).
We also detected that both caspase-1 activity and IL-1β secretion
(indicators of the NALP3 inﬂammasome activation) were upregu-
lated in a time-dependent manner in HG-treated podocytes
(Fig. 2C, D).
3.3. Suppression of the NALP3 inﬂammasome attenuates HG-induced
NALP3 inﬂammasome activation and podocyte injury
As shown in Fig. 3A–D, the inhibition of both NALP3 and ASC by
shRNA decreased HG-induced NALP3, ASC, active caspase-1 and active
IL-1β expression in HG-treated podocytes. Inhibiting caspase-1 by Z-
YVAD also impeded the pro-IL-1β cleavage. Also the interference above
inhibited caspase-1 activity (Fig. 3E) and IL-1β secretion (Fig. 3F) in
HG-exposed podocytes.
HG increased desmin expression and down-regulated synaptopodin
in podocytes, which was consistent with previous publication [32].
However, pretreatment with ASC/NALP3 shRNA or Z-YVAD reversed
the aforementioned effects (Fig. 4A–D). Besides, suppression of the
NALP3 inﬂammasome prevented HG-induced loss and rearrangement
of F-actin, a component, which is indispensable for reﬁned structure
and function of podocytes (Fig. 4E, F).
3.4. Caspase-1 deﬁciency suppresses NALP3 inﬂammasome function and
alleviates glomerular and podocyte injury in DN mice
Under DN conditions, caspase-1 activity was enhanced in the glo-
meruli of WTmice, whichwas proved by Green FLICA Caspase-1 Detec-
tion Kit (Fig. 5A). The caspase-1 activity was absolutely inhibited in the
glomeruli of caspase-1 KO mice under either normal or DN state. Also
knocking down caspase-1 hampered the formation of active IL-1β in
the glomerular lysate of DN mice (Fig. 5B, C).
We further investigatedwhether caspase-1 can participate in NALP3
inﬂammasome activation and glomerular/podocyte injury in DN mice.
As was shown in Table 1, after STZ injection for 8 weeks, blood glu-
cose signiﬁcantly increased in both DN-WT mice and DN-KO mice
compared to their respective controls, while there was no signiﬁcant
difference between them. Furthermore, although both DN-WT mice
and DN-KO mice indicated a remarkable decrease in body weight
and an obvious increase in kidney-to-body weight ratio compared
with that in their separate control mice, knocking out caspase-1 in
2451P. Gao et al. / Biochimica et Biophysica Acta 1843 (2014) 2448–2460DNmice obviously lowered kidney-to-bodyweight ratio. In addition,
after STZ injection, urine albumin to creatinine ratio (UACR) in-
creased 15-fold in both WT mice and KO mice, and caspase-1 deﬁ-
ciency did not alter albuminuria in the control mice, but reduced
30% UACR in the DN mice.
As shown in Fig. 6A, the pathological changes in the glomeruli ofWT
and KO mice were examined by PAS staining. It was found that the
average glomeruli damage index (GDI) was higher in both DN-WT
mice and DN-KO mice, while GDI in DN-KO mice was markedly lower
compared to DN-WTmice (Fig. 6B). Then we studied the ultrastructure
of podocytes under transmission electron microscopy (TEM). The
normal structure of podocyte foot processes was observed in both
Ctrl-WT mice and Ctrl-KO mice, whereas evident effacement of
podocyte foot processes was discovered in DN-WT mice. Notably
knocking down caspase-1 preserved the morphology of podocytes
(Fig. 6C). Next, we assessed the effect of caspase-1 on the podocyteM
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both Ctrl mice and DN mice. F. Summarized data of integrated optical density (IOD) (n = 7)impairment in DN mice. By indirect immunoﬂuorescent staining, we
found that podocin and synaptopodin arranged along the glomerular
capillary loop as a ﬁne linear-like pattern in the glomeruli of Ctrl-WT
mice and Ctrl-KO mice, but the staining of both podocin and
synaptopodin presented a dramatic decrease in the glomeruli of DN-
WT mice, which was reversed partly in DN-KO mice (Fig. 6D). Western
blot analyses also reconﬁrmed that podocin and synaptopodin protein
expression signiﬁcantly decreased in the glomerular lysate of DN-WT
mice; however, this phenomenon was not observed in the glomerular
lysate of DN-KO mice (Fig. 6E, F).
3.5. TXNIP expression is upregulated in podocytes of DN mice
To understand the molecular mechanism of NALP3 inﬂammasome
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Fig. 2. HG induces NALP3 inﬂammasome activation in cultured human podocytes. A.
Western-blotting gel documents showing the expression of NALP3, ASC, active caspase-1
and active IL-1β in cultured podocytes by HG. B. Protein expression of NALP3, ASC, active
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2452 P. Gao et al. / Biochimica et Biophysica Acta 1843 (2014) 2448–2460was shown that TXNIP was increased in the glomerular lysate of DN
mice (Fig. 7A, B). The upregulated TXNIPwas found tomainly distribute
in podocytes by confocal microscopy (Fig. 7C). Furthermore, in the
glomerular lysate of DN mice, the interaction between TXNIP and
NALP3 was strengthened as determined by co-immunoprecipitation
(Fig. 7D).
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We revealed that HG exposure induced intensive expression of TXNIP
in human podocyteswithin 48 h, which reached the peak at 48 h (Fig. 8A,B). What is more, TRX activity gradually time-dependently decreased
within 48 h in HG-exposed podocytes (Fig. 8C). By coimmunoprecip-
itation assay, we observed the interaction between TXNIP and NALP3 in
podocytes became gradually detectable as the HG exposure prolonged,
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Fig. 4. Inhibition of NALP3 inﬂammasome attenuates HG-induced podocyte injury. A. Western blot analyses of both podocyte injury marker desmin and podocyte marker synaptopodin
expression in culturedhumanpodocytes byASC/NALP3 shRNA. B. Protein expression of desmin and synaptopodin in culturedhumanpodocytes (n= 7–9). C.Western blot analyses show-
ing the effect of caspase-1 inhibitor Z-YVAD on the expression of desmin and synaptopodin in cultured human podocytes. D. Protein expression of desmin and synaptopodin in cultured
humanpodocytes (n= 8–9). E.Microscopic images of F-actin by rhodamine–phalloidin staining. F. Summarizeddata from counting the cellswith distinct, longitudinal F-actinﬁbers. Scor-
ingwasdetermined from100 podocytes on each slide (n=4). Ctrl:control; HG:high glucose; Veh:vehicle; Scram:scrambled shRNA; shASC: ASC shRNA; shNALP3:NALP3 shRNA. ⁎P b 0.05
vs. Ctrl; #P b 0.05 vs. HG.
2454 P. Gao et al. / Biochimica et Biophysica Acta 1843 (2014) 2448–2460which was more prominent after HG stimulation for 48 h. Inhibition of
TXNIP by siRNA prevented the interaction between TXNIP and NALP3
(Fig. 9A). Our results showed that TRX activity was impeded at 48 h of
HG stimulation, while it was reversed after knocking down TXNIP
expression (Fig. 9B). In addition, silencing TXNIP inhibited NALP3, active
caspase-1 and active IL-1β expression in cultured human podocytes
under HG treatment (Fig. 9C, D). Simultaneously, being consistent with
above ﬁndings, TXNIP gene silencing dramatically blocked the caspase-1 activity (Fig. 9E) and the IL-1β production (Fig. 9F) in HG-induced
podocytes.
3.7. Silencing TXNIP gene alleviates HG-induced podocyte injury
Knocking down TXNIP expression suppressed desmin expression
and preserved synaptopodin expression in podocytes exposed to HG
for 48 h (Fig. 10A, B). HG exposure disturbed the well-deﬁned F-actin
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Fig. 5. Caspase-1 deﬁciency suppresses NALP3 inﬂammasome function in the glomeruli of DNmice. A. Caspase-1 activity in the glomeruli of four groups of mice by Green FLICA Caspase-1
Detection Kit. Imageswere representative of six images per kidney from sevenmice per groups. B.Western blot analyses of IL-1β production induced by STZ in the glomerular lysate of the
four groups ofmice. C. Protein expression of IL-1β in the glomerular lysate of the four groups of mice (n=6). Ctrl-WT: control wide typemice; Ctrl-KO: control caspase-1 knockoutmice;
DN-WT: diabetic nephropathy wide type mice; DN-KO: diabetic nephropathy caspase-1 knockout mice. ⁎P b 0.05 vs. Ctrl-WT; #P b 0.05 vs. Ctrl-KO; &P b 0.05 vs. DN-WT.
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podocytes. Interestingly inhibition of TXNIP reversed this alteration
(Fig. 10C, D).
4. Discussion
The purpose of the present study was to examine whether and how
theNALP3 inﬂammasome is activated in podocytes and induces podocyte
and glomerular injury inDN.Our results demonstrated thatHGprompted
the NALP3 inﬂammasome expression and activation in cultured human
podocytes and in specimens derived from both human and murine
models of DN. These results suggest that the NALP3 inﬂammasome
activation may initiate podocyte injury and ultimately lead to podocyte
dysfunction in DN. However, both silencing the NALP3/ASC gene and
inhibiting the caspase-1 activity blockedNALP3 inﬂammasome activation
and injury in HG-induced podocytes. These results suggest that the
NALP3 inﬂammasome activation may be one of the major mechanisms
responsible for podocyte damage under HG.Moreover, we demonstrated
that TXNIP mediated the NALP3 inﬂammasome activation by interacting
with NALP3 in podocytes.Table 1
Physical and biochemical parameters of experimental animals.
Variable Ctrl-WT Ctrl-KO
Body weight (g) 23.44 ± 0.49 23.89 ± 2.
Kw/Bw (g/kg) 12.65 ± 0.66 12.27 ± 1.
Glucose (mmol/l) 5.76 ± 0.95 4.93 ± 0.
UACR (mg/g) 0.73 ± 0.25 0.71 ± 0.
Ctrl-WT: control wide type mice; Ctrl-KO: control caspase-1 knockout mice; DN-WT: diabetic n
kidney weight; Bw: body weight; UACR: urine albumin to creatinine ratio. Values are describe
⁎ P b 0.0001 vs. Ctrl-WT.
⁎⁎ P b 0.0001 vs. Ctrl-KO.
⁎⁎⁎ P b 0.05 vs. DN-WT.Numerous studies have been conducted on the mechanisms of non-
microbial and sterile inﬂammation, which have provided reasonable
explanations for the pathogenesis of various renal diseases [35]. It is
well known that renal inﬂammation and damage are mainly initiated
by resident cells. Additionally, IL-1β is involved in the progression of
human glomerulo-nephritis by inducing local inﬂammation, which
is mainly produced by podocytes [17]. Moreover, the activation of
NALP3 inﬂammasome causes the onset of non-microbial diseases
including diabetes [23,36]. Activated NALP3 inﬂammasome subse-
quently prompts caspase-1 activation and initiates pro-IL-1β and pro-
IL-18 cleavage into active mature forms [37]. In this regard, we hypoth-
esized that the NALP3 inﬂammasome was involved in podocyte injury
under HG. To test this hypothesis, our observation indicated that
NALP3 inﬂammasome components (e.g., NALP3, ASC, and caspase-1)
could colocalize with synaptopodin (the marker of podocytes) in the
glomeruli of both human DN specimens and DN mice, although the
intensity of synaptopodin staining decreased in the glomeruli of DN
mice. The increased expression of NALP3 inﬂammasome components
was reconﬁrmed in the glomeruli of DN mice by immunohistochemis-
try. These results suggest that the NALP3 inﬂammasome takes part inDN-WT DN-KO
29 14.70 ± 2.76⁎ 15.93 ± 2.65⁎⁎
36 19.72 ± 3.65⁎ 16.38 ± 1.17⁎⁎,⁎⁎⁎
61 36.25 ± 8.39⁎ 35.91 ± 13.35⁎⁎
15 25.4 ± 8.58⁎ 17.96 ± 3.71⁎⁎,⁎⁎⁎
ephropathy wide typemice; DN-KO: diabetic nephropathy caspase-1 knockout mice; Kw:
d as mean ± SEM for 6–8 mice in each group.
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Fig. 6.Caspase-1 deﬁciency attenuates STZ-inducedglomerular andpodocyte injury inDNmice. A. PAS staining showingglomerularmorphological changes. B. Summarizeddata ofGDI by semi-
quantitation of scores in the glomeruli of the four groups of mice (n = 7). For each kidney section, 50 glomeruli were randomly chosen for the calculation of GDI. C. Podocyte ultrastructure
changes by TEM examination. Images were representative of six TEM images per kidney from threemice per group, bars= 1 μm. D. Immunoﬂuorescent staining of podocin and synaptopodin
in the glomeruli of the four groupsofmice (n=7). E.Western-blotting gel documents showing the expressionof podocin and synaptopodin in the glomerular lysate of the four groups ofmice. F.
Protein expressionof podocin and synaptopodin in theglomerular lysate of the four groupsofmice (n=8). Ctrl-WT: controlwide typemice; Ctrl-KO: control caspase-1 knockoutmice;DN-WT:
diabetic nephropathy wide type mice; DN-KO: diabetic nephropathy caspase-1 knockout mice. ⁎P b 0.05 vs. Ctrl-WT; #P b 0.05 vs. Ctrl-KO; &P b 0.05 vs. DN-WT.
2456 P. Gao et al. / Biochimica et Biophysica Acta 1843 (2014) 2448–2460podocyte damage of DN. Furthermore, in vitro HG induced the expres-
sion and activation of NALP3 inﬂammasome in a time-dependent man-
ner in cultured human podocytes. The caspase-1 activity and IL-1β
production were increased simultaneously. Thus, it was proposed that
HG stimulation could directly promote NALP3 inﬂammasome activation
in podocytes.
To clarify the role of NALP3 inﬂammasome in podocyte injury under
HG, we suppressed NALP3 inﬂammasome activation by shRNA or a
speciﬁc inhibitor. We found that both ASC/NALP3 shRNA and inhibition
of caspase-1 activity by Z-YVAD prevented caspase-1 activation and the
cleavage of pro-IL-1β. As we know, IL-1β is an important proinﬂamma-
tory cytokine, which controls the outcome of renal disease. In clinicaltrials, inhibition of IL-1β ameliorates type 2 diabetes [38]. In our present
study, it was found that both silencing the ASC/NALP3 gene and inhibi-
tion of caspase-1 activity by Z-YVAD reduced the expression of desmin
and rescued weakened synaptopodin expression in HG-stimulated
podocytes. Desmin is a speciﬁc and sensitive indicator of the impaired
podocyte [39] and its expression is usually upregulated when podocyte
damage occurs [40]. Synaptopodin plays a role in adjusting the shape
andmovement of foot processes [41]. Collectively, these results indicated
that blockade of NALP3 inﬂammasome activation prevented podocyte
injury under HG.
Because the NALP3 inﬂammasome activation was involved in
podocyte injury under HG and caspase-1 is a key component and
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Fig. 7. TXNIP expression is upregulated in podocytes of DN mice. A. The expression of
TXNIP in the glomerular lysate of both controlmice andDNmice byWestern blot analyses.
B. Summarized data of the protein expression of TXNIP (n = 7). C. The co-localization of
TXNIPwith synaptopodin by confocalmicroscopic analysis in the glomeruli of both control
mice and DN mice. D. Interaction of TXNIP with NALP3 in the glomerular lysate of both
control mice and DN mice by co-immunoprecipitation. Ctrl mice:control mice; DN mice:
diabetic nephropathy mice; IP: immunoprecipitation. ⁎P b 0.05 vs. Ctrl.
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Fig. 8. HG increases the expression of TXNIP and reduces TRX activity in cultured human
podocytes. A. Western-blotting gel documents showing the expression of TXNIP in cultured
human podocytes byHG. B. Summarized data of TXNIP protein expression in podocyteswith
or without stimulation of HG (n= 6). C. TRX activity in podocytes with or without HG over
time (n = 4). Ctrl:control; HG:high glucose; Veh:vehicle. ⁎P b 0.05 vs. Ctrl.
2457P. Gao et al. / Biochimica et Biophysica Acta 1843 (2014) 2448–2460mediator of the function of NALP3 inﬂammasome,we used caspase-1 KO
mice to explore whether the NALP3 inﬂammasome activation affected
the process of DN in vivo. We ﬁrst found that caspase-1 deﬁciency
reduced the cleavage of pro-IL-1β in the glomerular lysate of DN-KO
mice, and then we examined its effect on glomerular and podocyte inju-
ry. The DN-KO mice exhibited a signiﬁcant (i.e., 30%) reduction in urinealbumin to creatinine ratio as compared with that of DN-WT mice. This
implied that knocking out caspase-1 prevented renal injury in DN
mice. By PAS staining, the glomerulosclerosis in DN-KO mice was
evidently reduced, which further supported the view that the NALP3
inﬂammasome was essential for the pathogenesis of DN. It was shown
for the ﬁrst time that HG induced podocyte damage by triggering
NALP3 inﬂammasome activation, which was afﬁrmed by detecting the
expression of slit diaphragm molecule podocin, and expression of the
cytoskeletal molecule synaptopodin. It is also commonly appreciated
that, podocin is one of the slit diaphragm complexes, and is critical for
maintaining normal glomerular ﬁltration barrier structure and function.
In addition, synaptopodin has the capacity to adjust the shape and
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Fig. 9. Silencing TXNIPmitigates the activation of NALP3 inﬂammasome. A.Western blot analyses of the interaction of TXNIPwith NLRP3 by co-immunoprecipitation of TXNIP in cultured
human podocytes. B. TRX activity (n=5). C.Western-blotting gel documents showing the expression of TXNIP, active caspase-1 and active IL-1β in cultured humanpodocyteswithHGby
siTXNIP. D. The protein expression of TXNIP, active caspase-1 and active IL-1β by siTXNIP (n = 5–6). E. Caspase-1 activity (n = 4). F. IL-1β production (n = 4). Ctrl:control; HG:high
glucose; Veh:vehicle; Scram:scrambled siRNA; siTXNIP: TXNIP siRNA; IP:immunoprecipitation. ⁎P b 0.05 vs. Ctrl; #P b 0.05 vs. HG.
2458 P. Gao et al. / Biochimica et Biophysica Acta 1843 (2014) 2448–2460movement of the foot processes [41]. By immunoﬂuorescent staining and
Western blotting, we demonstrated that the expression of synaptopodin
and podocin in the glomeruli of DN-KOmice was higher than that of the
glomeruli of DN-WT mice, which further implied that podocyte injury
was markedly attenuated by caspase-1 blockade. Collectively, these
observations elucidated that HG could activate NALP3 inﬂammasome in
podocytes and glomeruli, which may be involved in the pathogenesis of
early podocyte and glomerular injury during DN.
To further explore themolecularmechanismofNALP3 inﬂammasome
activation under HG, we detected whether TXNIP mediated this process
and resulted in podocyte injury. It was reported that TXNIP is an impor-
tant player in the DN pathogenesis [25,42]. Zhou et al. also uncovered
that TXNIP is indispensable for hyperglycemia-induced and caspase-1-
dependent IL-1β production in mouse pancreatic β-cells, and that
TXNIP binds with NALP3 andmediates NALP3 inﬂammasome activation
in THP-1 cells [23].In our study, itwas found that TXNIP expressionwas increased in the
glomerular lysate of DNmice, and the increased TXNIP was mainly dis-
tributed in podocytes of the glomeruli by confocal microscopic analysis.
In addition, the interaction between TXNIP andNALP3was strengthened
in the glomerular lysate of DN mice by co-immunoprecipitation, which
implied that TXNIP was involved in podocyte injury of DN by activating
NALP3 inﬂammasome. Consistently, we elucidated that HG prompted
TXNIP expressionwithin 48 h,which reached the peak at 48h in cultured
human podocytes. By co-immunoprecipitation we also showed an in-
creased interaction between TXNIP and NALP3 in HG-stimulated
podocytes. Silencing the TXNIP gene prevented NALP3 inﬂammasome
activation and reversed podocyte injury in HG, which was similar to
the effects aroused by inhibition of NALP3/ASC. Moreover, TRX activity
was gradually and time-dependently reduced within 48 h in HG-
stimulated podocytes, but it was reversed after knocking down TXNIP
expression. The results above inferred that TXNIP activated NALP3
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Fig. 10. Silencing TXNIP alleviates HG-induced podocyte injury. A. Western-blotting gel
documents showing the effect of inhibition of TXNIP on HG-induced expression of both
podocyte injury marker desmin and podocyte marker synaptopodin in cultured human
podocytes. B. Protein expression of desmin and synaptopodin in cultured human podocytes
(n = 7–8). C. Microscopic images of F-actin by rhodamine–phalloidin staining. D. Summa-
rized data fromcounting the cellswith distinct, longitudinal F-actin ﬁbers. Scoringwas deter-
mined from100podocytes on each slide (n=5). Ctrl:control; HG:high glucose; Veh:vehicle;
Scram:scrambled siRNA; siTXNIP: TXNIP siRNA. ⁎P b 0.05 vs. Ctrl; #P b 0.05 vs. HG.
2459P. Gao et al. / Biochimica et Biophysica Acta 1843 (2014) 2448–2460inﬂammasome and in turn impaired podocyte structure and function
under HG. How TXNIP mediates NALP3 inﬂammasome activation is
an important study for us to explore in the future.
In summary, our studydemonstrates that theNALP3 inﬂammasome is
involved in podocyte injury, and the early stage of glomerular damage in
DN. In addition, TXNIP can mediate NALP3 inﬂammasome activation and
initiate IL-1β production, eventually leading to podocyte and glomerularimpairment. Our current data suggest a new mechanism of podocyte
injury during DN.Acknowledgements
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